Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M500219200 on March 18, 2005

J. Biol. Chem., Vol. 280, Issue 19, 18696-18702, May 13, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/19/18696    most recent
M500219200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camden, J. M.
Right arrow Articles by Weisman, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camden, J. M.
Right arrow Articles by Weisman, G. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

P2Y2 Nucleotide Receptors Enhance {alpha}-Secretase-dependent Amyloid Precursor Protein Processing*

Jean M. Camden{ddagger}, Ann M. Schrader{ddagger}, Ryan E. Camden{ddagger}, Fernando A. González§, Laurie Erb{ddagger}, Cheikh I. Seye{ddagger}, and Gary A. Weisman{ddagger}

From the {ddagger}Department of Biochemistry, University of Missouri-Columbia, Columbia, Missouri 65211 and the §Department of Chemistry, University of Puerto Rico, Río Piedras, Puerto Rico 00931

Received for publication, January 6, 2005 , and in revised form, March 8, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The amyloid precursor protein (APP) is proteolytically processed by {beta}- and {gamma}-secretases to release amyloid {beta}, the main component in senile plaques found in the brains of patients with Alzheimer disease. Alternatively, APP can be cleaved within the amyloid {beta} domain by {alpha}-secretase releasing the non-amyloidogenic product sAPP{alpha}, which has been shown to have neuroprotective properties. Several G protein-coupled receptors are known to activate {alpha}-secretase-dependent processing of APP; however, the role of G protein-coupled nucleotide receptors in APP processing has not been investigated. Here it is demonstrated that activation of the G protein-coupled P2Y2 receptor (P2Y2R) subtype expressed in human 1321N1 astrocytoma cells enhanced the release of sAPP{alpha} in a time- and dose-dependent manner. P2Y2 R-mediated sAPP{alpha} release was dependent on extracellular calcium but was not affected by 1,2-bis(2-aminophenoxy)ethane-N,N,N,-trimethylammonium salt, an intracellular calcium chelator, indicating that P2Y2 R-stimulated intracellular calcium mobilization was not involved. Inhibition of protein kinase C (PKC) with GF109203 or by PKC down-regulation with phorbol ester pre-treatment had no effect on UTP-stimulated sAPP{alpha} release, indicating a PKC-independent mechanism. U0126, an inhibitor of the mitogen-activated protein kinase pathway, partially inhibited sAPP{alpha} release by UTP, whereas inhibitors of Src-dependent epidermal growth factor receptor transactivation by P2Y2 Rs had no effect. The metalloprotease inhibitors phenanthroline and TAPI-2 and the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone also diminished UTP-induced sAPP{alpha} release. Furthermore, small interfering RNA silencing of an endogenous adamalysin, ADAM10 or ADAM17/TACE, partially suppressed P2Y2R-activated sAPP{alpha} release, whereas treatment of cells with both ADAM10 and ADAM17/TACE small interfering RNAs completely abolished UTP-activated sAPP{alpha} release. These results may contribute to an understanding of the non-amyloidogenic processing of APP.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
P2 nucleotide receptors modulate a wide range of physiological responses following their activation by extracellular nucleotides (1, 2). The G protein-coupled P2Y2 receptor (P2Y2R)1 subtype is fully activated by equivalent concentrations of ATP or UTP (3–5) and is up-regulated in salivary gland models of stress and disease (6–8) as well as in blood vessels after balloon angioplasty and in collared carotid arteries, where it induces intimal hyperplasia and inflammation by increasing smooth muscle cell proliferation and leukocyte infiltration (9, 10). Moreover, nucleotides are released from damaged cells of all tissues and from excited neurons, aggregating platelets, and contracting smooth muscle under physiological conditions (2, 11).

The diversity of cellular responses mediated by P2Y2Rs is due in part to unique structural features that enable these receptors to stimulate a variety of signal transduction pathways. In addition to the classical stimulation of G{alpha}q-dependent phospholipase C (12, 13), the P2Y2R contains two Src homology 3 binding sites (PXXP motifs) in its intracellular C terminus that interact directly with Src to transactivate epidermal growth factor (EGF), platelet-derived growth factor, and vascular epidermal growth factor receptor 2 receptors (14, 15). The P2Y2R also contains an Arg-Gly-Asp sequence in the first extracellular loop, which has been shown to interact with {alpha}v{beta}3/{beta}5 integrins (16) that regulate cell chemokinesis and chemotaxis (17–19), responses associated with cell-mediated inflammation (20). Activation of the P2Y2R on endothelial cells and astrocytes also up-regulates the expression of cell surface adhesion molecules that play a role in monocyte-mediated inflammation (21) and reactive astrogliosis,2 respectively. The present study describes a novel function for the P2Y2R in enhancing the {alpha}-secretase-dependent cleavage of the amyloid precursor protein (APP) to generate a neuroprotective peptide rather than neurodegenerative A{beta}, a finding that has relevance to Alzheimer disease.

APP is a transmembrane glycoprotein that is present in a variety of tissues but predominantly in the brain (22). APP contains an extracellular N terminus and a short C-terminal region that lies in the cytoplasm. Within APP, a single membrane-spanning region of 39–42 amino acids represents the amyloidogenic A{beta} peptide, the major component of plaques found in Alzheimer patients (23, 24). Proteolytic cleavage of APP in vivo can occur at the amino terminus of the A{beta} domain ({beta}-cleavage), within the A{beta} domain ({alpha}-cleavage), and at the C terminus of the A{beta} domain ({gamma}-cleavage); for review see Mills and Reiner (25). Cleavage of the APP protein by both {beta}-secretase and {gamma}-secretase gives rise to the amyloidogenic A{beta} fragment. APP cleavage by {alpha}-secretase generates sAPP{alpha}, a soluble, non-amyloidogenic N-terminal fragment (~100–140 kDa) that is released into the extracellular medium, whereas the membrane-retained fragment undergoes further cleavage and endocytotic processing (26–28). The sAPP{alpha} fragment has been shown to have both neurotrophic (29) and neuroprotective (30–33) activities, suggesting that the presence of sAPP{alpha} in the external milieu may promote neuronal viability.

Stimulation of several G protein-coupled receptors (GPCRs) has been reported to induce sAPP{alpha} release through the activation of protein kinase C (PKC)-dependent and -independent pathways (34–36). Initial studies conducted in HEK293 cells showed that overexpression of the human M1 and M3 muscarinic receptors stimulated sAPP{alpha} secretion (37). Subsequently, G protein-coupled glutamate, serotonin (5-HT), thrombin, and bradykinin receptors have been shown to regulate sAPP{alpha} release (38–43). Furthermore, receptor-mediated activation of sAPP{alpha} release is associated with a reduction in A{beta} formation (44–46). Although the molecular identities of the secretase(s) stimulated by GPCRs have not been fully elucidated, both constitutive and receptor-regulated sAPP{alpha} release have been linked to two members of the ADAM (a disintegrin and metalloprotease) family, namely ADAM 10, which is the Kuz enzyme (47), and ADAM17/TACE (tumor necrosis factor-{alpha} converting enzyme), which is the protease responsible for releasing tumor necrosis factor-{alpha} (TNF-{alpha}) from the plasma membrane (48). In the present study we demonstrate that activation of a P2Y2 nucleotide receptor expressed in the human 1321N1 astrocytoma cells stimulates ADAM10-mediated APP processing and ADAM17/TACE-mediated APP processing, leading to the release of sAPP{alpha}. Because nucleotide release from damaged cells in the central nervous system would be expected to activate P2Y2Rs, these findings suggest a novel neuroprotective role for P2Y2R-mediated APP processing in neurodegenerative disorders, including Alzheimer disease.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—All chemicals and reagents were purchased from Sigma unless stated otherwise. Cell culture medium, fetal bovine serum, and G418 were obtained from Invitrogen. U0126, AG1478 and the pyrazole pyrimidine-type 2 inhibitor (PP2) were purchased from Calbiochem. TNF-{alpha} protease inhibitor (TAPI-2) was purchased from Peptides International (Louisville, KY), and decanoyl-Arg-Val-Lys-Arg-chloromethylketone (CMK) was purchased from Bachem (Torrance, CA).

Cell Culture—Human 1321N1 astrocytoma cells stably transfected with human P2Y2R cDNA (5) were cultured in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 500 µg/ml G418 and maintained at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. Cells transfected with a pLXSN expression vector served as a negative control.

sAPP{alpha} Release—Cells were plated on 12-well culture dishes and grown until ~80–90% confluence. Cells were washed twice with a modified Krebs-HEPES buffer (15 mM HEPES, pH 7.4, 120 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1 mM CaCl2, and 10 mM D-glucose) and then incubated on a rocking platform in a humidified incubator at 37 °C for specified times with 200 µl of buffer containing compounds as indicated in the Fig. 4 legend. When indicated, cells were pretreated with inhibitors for 30 min prior to the addition of nucleotides. At the end of the incubation period, the medium was collected, centrifuged at 12,000 x g for 1 min to remove cellular debris, and the protein concentration of the supernatant was determined by the Lowry method (49). 80 µg of supernatant protein was diluted 1:4 with 5x Laemmli buffer, boiled for 3 min, subjected to electrophoresis on 7.5% SDS-polyacrylamide mini-gels, and transferred to nitrocellulose membranes. Membranes were blocked for 1 h with 5% (w/v) nonfat dry milk in TBST (Tris-buffered saline containing 0.1% (v/v) Tween 20) and immunoblotted overnight at 4 °C in 3% (w/v) bovine serum albumin with 0.02% (w/v) sodium azide in TBST with a 6E10 monoclonal antibody (1:1000 dilution; Senetek, Maryland Heights, MO) that recognizes residues 1–17 of the A{beta} domain of sAPP{alpha} (50). Membranes were washed three times during a 45-min period with TBST and incubated with peroxidase-linked goat anti-mouse IgG antibody (1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 1 h. After three more washes with TBST, the membrane was subjected to chemiluminescence, and the protein bands detected on x-ray film were quantified using a computer-driven scanner and Quantity One software (Bio-Rad). The amount of sAPP{alpha} generated was expressed as a percentage of untreated controls. All experiments were performed in duplicate and repeated at least three times. Analysis of variance and unpaired Student's t test was used to determine statistical significance (p < 0.05).

Measurement of the Intracellular Calcium Concentration—The intracellular free calcium concentration ([Ca2+]i) was measured by dual excitation spectrofluorometric analysis of cell suspensions loaded with fura-2 (6) and BAPTA as described previously (51). Cells were assayed in modified Krebs-HEPES buffer containing 0.1% (w/v) bovine serum albumin. The intracellular calcium concentration was calculated by the method of Grynkiewicz et al. (52).

siRNA Targeting of ADAM10 and ADAM17/TACE Genes—Transfection of cells with siRNA duplexes (Integrated DNA Technologies, Coralville, IA) to inhibit endogenous ADAM10 or ADAM17/TACE expression was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Briefly, 0.7 µg of each of the three ADAM10 or ADAM17/TACE siRNA duplexes was incubated with cells in serum-free medium for 6 h and then replaced with normal growth media. Sequences of the siRNA duplexes were AUUCGUAGGUUGAAAUGUCdTdT, UUCCAUUUCCACAAAUAGGdTdT, and AGCCAUUACAUAUUCCUUCdTdT (ADAM10) and AGUUUGCUUGGCACACCUUdTdT, AGUAAGGCCCAGGAGUGUdTdT, and CAUAGAGCCACUUUGGAGAdTdT (ADAM17/TACE). Cells were assayed for sAPP{alpha} release 48 h after siRNA transfection, and silencing of the targeted protein expression was confirmed by Western analysis of cell lysates as described above for the detection of sAPP{alpha} by using goat anti-human ADAM17/TACE antibody (1:1000 dilution; Santa Cruz Biotechnology) or goat anti-human ADAM10 antibody (1:1000 dilution; Sigma). Blots were stripped and reprobed with goat anti-human actin antibody (1: 1000 dilution; Cytoskeleton, Denver, CO) to verify the equivalence of protein loading per lane.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
P2Y2R Activation Stimulates the Release of sAPP{alpha}—UTP (100 µM) caused a time-dependent increase in sAPP{alpha} (~120 kDa) release from human 1321N1 astrocytoma cells stably transfected with P2Y2R cDNA (1321N1-P2Y2 cells) that was significantly greater than basal sAPP{alpha} release (Fig. 1, A and B). UTP also caused a dose-dependent increase in sAPP{alpha} from 1321N1-P2Y2 cells with an EC50 value of 2.5 µM (Fig. 2), which is characteristic of P2Y2R activation (5, 6, 53, 54). In contrast, UTP-induced sAPP{alpha} release was undetectable in untransfected cells or in cells transfected with the expression vector only (data not shown).



View larger version (42K):
[in this window]
[in a new window]
  		FIG. 1.
P2Y2R activation causes a time-dependent release of sAPP{alpha}. A, representative Western blot of medium from 1321N1-P2Y2 cells stimulated with UTP (100 µM) or PMA (1 µM) for the times indicated. Equivalent amounts of protein in each lane were analyzed for sAPP{alpha} as described under "Experimental Procedures." Blot shown is representative of results from three experiments. B, time course of basal ({square}) and UTP-stimulated ({triangleup}) sAPP{alpha} release expressed as a percentage of maximal UTP-stimulated sAPP{alpha} release (at 180 min). Data points represent the means ± S.E. of results from three experiments. All UTP-induced time points are statistically different from the corresponding basal time points (p < 0.05).

 



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 2.
UTP induces a dose-dependent release of sAPP{alpha} from 1321N1-P2Y2 cells. Cells were stimulated for 2 h with the indicated concentration of UTP (0.1–100 µM), and sAPP{alpha} release into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release is expressed as a percentage increase over basal levels. Data points represent the means ± S.E. of results from four experiments.

 
UTP-induced sAPP{alpha} Release Is Independent of PKC Activation—The PKC activator phorbol myristate acetate (PMA; 1 µM) also caused a time-dependent release of sAPP{alpha}, similar to that caused by UTP (Fig. 1A). Because P2Y2R activation causes the phospholipase C-dependent stimulation of PKC (1), we determined whether P2Y2R-mediated sAPP{alpha} release is dependent on activation of PKC. Therefore, 1321N1-P2Y2 cells were pre-treated for 30 min with GF109203 (10 µM), an inhibitor of PKC, followed by incubation with UTP (100 µM) or PMA (1 µM) for an additional 2 h. GF109203 completely inhibited PMA-activated release of sAPP{alpha} but had no effect on UTP-induced release (Fig. 3A). Furthermore, PKC down-regulation by overnight treatment with PMA (1 µM) abolished PMA-stimulated sAPP{alpha} release but had no effect on the UTP-induced sAPP{alpha} release (Fig. 3B). Thus, UTP-induced sAPP{alpha} release is independent of P2Y2R-mediated activation of PKC.



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 3.
UTP-induced sAPP{alpha} release is independent of PKC. A, human 1321N1-P2Y2 cells were pretreated for 30 min with GF109203 (10 µM) and stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. Then, sAPP{alpha} release into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release and PMA-induced sAPP{alpha} release are expressed as a percentage increase over basal levels. Data represent the means ± S.E. of results from three experiments where the asterisk (*) represents p < 0.05, indicating a significant difference from PMA-stimulated control. B, PKC was down-regulated in 1321N1-P2Y2 cells by pre-incubation with PMA (1 µM) for 24 h, and then the cells were incubated with UTP (100 µM) or PMA (1 µM) for 2 h. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release and PMA-induced sAPP{alpha} release are expressed as a percentage increase over basal levels. Data represent the means ± S.E. of results from three experiments where the asterisk (*) represents p < 0.05, indicating a significant difference from PMA-stimulated control.

 
UTP-induced sAPP{alpha} Release Is Dependent on Extracellular Calcium but Not P2Y2R-mediated Intracellular Calcium Mobilization—Activation of G protein-coupled P2Y2Rs with UTP in 1321N1-P2Y2 cells is known to cause increases in [Ca2+]i through the G{alpha}q-dependent stimulation of phospholipase C, the generation of inositol-1,4,5 triphosphate, and the release of calcium from inositol-1,4,5 triphosphate-sensitive calcium stores (12, 13). In addition, P2Y2Rs can promote calcium entry through the stimulation of plasma membrane calcium channels (5, 13, 54, 55). Therefore, we examined the role of calcium signaling pathways in UTP-induced sAPP{alpha} release. In the absence of extracellular calcium, UTP-stimulated sAPP{alpha} release was completely inhibited (Fig. 4A). In contrast, PMA-stimulated sAPP{alpha} release was unaffected by the absence of extracellular calcium, suggesting the existence of both calcium entry-dependent and -independent pathways for stimulating sAPP{alpha} release. Unexpectedly, introduction into 1321N1-P2Y2 cells of the intracellular calcium chelator BAPTA, which suppresses P2Y2R-mediated increases in [Ca2+]i (Fig. 4B), had no effect on sAPP{alpha} release induced by UTP (Fig. 4A). These data suggest that sAPP{alpha} release due to P2Y2R activation is independent of increases in cytosolic calcium. Consistent with this conclusion, neither ionomycin, a calcium ionophore, nor thapsigargin, an inhibitor of the plasma membrane Ca2+-ATPase, caused an increase in sAPP{alpha} release (data not shown).

Inhibition of MAPK (ERK1/2) Partially Inhibits UTP-stimulated sAPP{alpha} Release—Previous studies in our laboratory have shown that UTP activates ERK1/2 phosphorylation in 1321N1-P2Y2 cells, in part via the Src-dependent transactivation of the EGF and platelet-derived growth factor receptors (14), consistent with Src-dependence of ERK1/2 phosphorylation by other GPCRs (56, 57). Therefore, we investigated the role of the MAPK/EGF receptor (EGFR) pathway in UTP-stimulated sAPP{alpha} release. U0126, an inhibitor of MAPK/ERK kinase (MEK) whose substrates are ERK1/2, partially inhibited (~40%) sAPP{alpha} release induced by UTP but not by PMA (Fig. 5). Incubation of cells with the Src inhibitor pyrazole pyrimidine-type 2 (10 µM) or the EGFR kinase inhibitor AG1478 (10 µM) had no effect on the UTP-stimulated or PMA-stimulated sAPP{alpha} release (data not shown). These results suggest that UTP-stimulated sAPP{alpha} release in 1321N1-P2Y2 cells is partially dependent on phosphorylation of ERK1/2 but independent of Src and EGFR activation.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 4.
Role of calcium in UTP-stimulated sAPP{alpha} release from 1321N1-P2Y2 cells. A, human 1321N1-P2Y2 cells were incubated in either calcium-containing Krebs-HEPES buffer or calcium-free Krebs-HEPES buffer with 0.2 mM EGTA and stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. Other cells were pre-loaded with BAPTA by preincubation with BAPTA-AM (25 µM) for 30 min and then stimulated with 100 µM UTP in calcium-containing Krebs-HEPES buffer. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release and PMA-induced sAPP{alpha} release are expressed as a percentage increase over basal levels Data represent the means ± S.E. of results from three experiments where double asterisks (**) represent p < 0.001, indicating a significant difference from UTP-stimulated control. B, cells were incubated for 30 min with fura 2-AM (2 µM) without or with BAPTA-AM (25 µM) and then stimulated with UTP (100 µM). Time-dependent increases in [Ca2+]i were determined as described under "Experimental Procedures."

 



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 5.
Effect of the MEK inhibitor U0126 on UTP-stimulated sAPP{alpha} release. Human 1321N1-P2Y2 cells were pretreated for 30 min with U0126 (1 µM) and then stimulated with UTP (100 µM) for 2 h. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release is expressed as a percentage increase over basal levels. Data represent the means ± S.E. of results from six experiments where the asterisk (*) represents p < 0.05, indicating a significant difference from UTP-stimulated control.

 
Inhibitors of Metalloproteases and Furin, the Proprotein Convertase, Decrease UTP-induced sAPP{alpha} Release—Disintegrin metalloproteases, including ADAM10 and ADAM17/TACE, catalyze the shedding of the ectodomain of APP and other transmembrane proteins (58). We determined that P2Y2R-mediated sAPP{alpha} release was inhibited by phenanthroline, a broad range metalloprotease inhibitor, and TAPI-2, a selective, competitive inhibitor of ADAM17/TACE (Fig. 6). PMA-stimulated sAPP{alpha} release was also inhibited by phenanthroline and TAPI-2 (Fig. 6A). TAPI-2 inhibited UTP-stimulated sAPP{alpha} release with an estimated IC50 of 1.8 µM (Fig. 6B), comparable with a value reported previously for the inhibition of ADAM17/TACE (59, 60). These results confirm that APP processing due to P2Y2R activation requires metalloprotease activity and that ADAM17/TACE is likely involved. However, micromolar concentrations of TAPI-2 have been reported to inhibit other members of the adamalysin family (61), which may contribute to P2Y2R-mediated sAPP{alpha} release.



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 6.
Inhibitors of metalloproteases prevent UTP-induced sAPP{alpha} release. A, human 1321N1-P2Y2 cells were pretreated for 30 min with phenanthroline (1 mM) and then stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release and PMA-induced sAPP{alpha} release are expressed as a percentage increase over basal levels. Data are the means ± S.E. of results from three experiments where the asterisk (*), representing p < 0.05, and the pound sign (#), representing p < 0.05, indicate significant differences from UTP-stimulated or PMA-stimulated controls, respectively. B, human 1321N1-P2Y2 cells were pretreated for 30 min with the indicated concentration of TAPI-2 and then stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." UTP-induced sAPP{alpha} release is expressed as a percentage increase over basal levels. Data represent the means ± S.E. of results from three experiments.

 
ADAM10 and ADAM17/TACE require proteolytic processing to become active (62). The proprotein convertase furin has been linked to the proteolytic cleavage of adamalysins (63, 64), and, therefore, we tested the ability of the furin inhibitor, CMK, to suppress UTP-induced sAPP{alpha} release. As shown in Fig. 7, both basal and UTP-stimulated sAPP{alpha} release were completely inhibited by CMK, suggesting that both constitutive and receptor-mediated sAPP{alpha} release via metalloproteases in 1321N1-P2Y2 cells are dependent on furin or a furin-like protease.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 7.
The furin inhibitor CMK prevents UTP-stimulated sAPP{alpha} release and PMA-stimulated sAPP{alpha} release. Representative Western blot of medium from 1321N1-P2Y2 cells pretreated for 24 h with CMK (20 µM) and then stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. Equivalent amounts of protein in each lane were analyzed for sAPP{alpha} as described under "Experimental Procedures." Blot shown is representative of results from three experiments.

 
ADAM10 and ADAM17/TACE Are Involved in UTP-stimulated sAPP{alpha} Release—To unambiguously determine whether ADAM10 and/or ADAM17/TACE were the metalloproteases responsible for P2Y2R-mediated sAPP{alpha} release, 1321N1-P2Y2 cells were transfected with ADAM10 and/or ADAM17/TACE siRNAs to inhibit expression of the endogenous adamalysins. Inhibition of either ADAM10 or ADAM17/TACE expression with the corresponding siRNAs partially inhibited basal, UTP-stimulated, and PMA-stimulated sAPP{alpha} release (Fig. 8A), whereas the simultaneous inhibition of both ADAM10 and ADAM17/TACE expression virtually prevented sAPP{alpha} release induced by either UTP or PMA (Fig. 8A). The extent of suppression of ADAM10 and ADAM17/TACE protein expression by the siRNAs is shown in Fig. 8B. Based on these data, we conclude that ADAM10 and ADAM17/TACE are the primary metalloproteases responsible for P2Y2R-mediated APP processing in 1321N1-P2Y2 cells.



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 8.
P2Y2R-mediated APP processing requires ADAM10 and ADAM17/TACE. A, representative Western blot of medium from 1321N1-P2Y2 cells with or without transfection of siRNA ADAM10 (siAdam10) and (siAdam10+17)/or siRNA ADAM17/TACE (siAdam17) and then stimulated with UTP (100 µM) or PMA (1 µM) for 2 h. The release of sAPP{alpha} into the medium was analyzed as described under "Experimental Procedures." B, Western blot of 1321N1-P2Y2 cells with or without transfection of siRNA ADAM10 (siADAM10) or siRNA ADAM17/TACE (siADAM17). The blot containing equivalent amounts of protein in each lane was probed with anti-ADAM10, anti-ADAM17/TACE, or anti-actin antibodies and is representative of results from three independent experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this report, we demonstrate that activation of the G protein-coupled P2Y2 nucleotide receptor subtype stimulates the {alpha}-secretase-dependent processing of APP. Utilizing the human 1321N1 astrocytoma cell line that lacks endogenous P2 receptor expression, we demonstrate that stable transfection with P2Y2R cDNA promoted UTP-induced release of sAPP{alpha} in a time- and dose-dependent manner, similar to sAPP{alpha} release mediated by muscarinic, glutamate, bradykinin, and serotonergic receptors (37–42).

G protein-coupled receptors have been shown to stimulate {alpha}-secretase-dependent APP processing via PKC-dependent and PKC-independent pathways (34–36, 65). Nonetheless, stimulation of either pathway can lead to activation of the same proteolytic enzyme (65). Here, we show that P2Y2R-mediated sAPP{alpha} release occurred independently of PKC activation because the PKC inhibitor GF109203 (Fig. 3A) or PKC down-regulation (Fig. 3B) had no effect on UTP-induced APP processing, although direct activation of PKC with the phorbol ester PMA increased sAPP{alpha} release and was inhibited by GF109203 or PKC down-regulation (Fig. 3), in agreement with previous reports (66, 67). Although P2Y2Rs in 1321N1-P2Y2 cells are known to activate PKC (1) these data indicate that activation of PKC is not necessary for P2Y2R-mediated increases in APP processing, suggesting the involvement of other cellular signaling pathways coupled to the P2Y2R in UTP-induced sAPP{alpha} release.

It is well known that activation of the P2Y2R causes an increase in [Ca2+]i through both the PLC-dependent release of calcium from intracellular stores and the entry of extracellular calcium through ion-activated calcium channels (1, 12). Several physiological responses resulting from P2Y2R activation are dependent on the rise of [Ca2+]i (e.g. ion secretion, fluid secretion, and vascular cell adhesion molecule-1 expression) (21, 54, 68); however, our results indicate that P2Y2R-mediated increases in [Ca2+]i by either calcium released from intracellular stores or calcium influx were not required for sAPP{alpha} release, because chelation of intracellular calcium with BAPTA had no effect on UTP-induced sAPP{alpha} release (Fig. 4A). Furthermore, incubation with ionomycin or thapsigargin, agents that increase [Ca2+]i, did not promote sAPP{alpha} release (data not shown), confirming that APP processing in 1321N1-P2Y2 cells is not a result of an increase of cytosolic calcium. However, the absence of extracellular calcium does inhibit UTP-induced but not PMA-induced sAPP{alpha} release (Fig. 4A), suggesting the presence of an extracellular calcium-dependent protein that regulates P2Y2R-mediated {alpha}-secretase activity. Because PKC-regulated {alpha}-secretase is found to be localized to the trans-Golgi network and not at the cell surface (69), it is possible that the PKC-independent {alpha}-secretase expressed in 1321N1-P2Y2 cells is localized to the cell surface where its activity could be modulated by the extracellular calcium concentration. Nonetheless, the role of extracellular calcium in P2Y2R-mediated sAPP{alpha} release requires further investigation.

Our data indicate that UTP-stimulated sAPP{alpha} release in 1321N1-P2Y2 cells is partially dependent on the activation of ERK1/2 (Fig. 5). Activation of GPCRs, including the P2Y2R, has been shown to stimulate ERK1/2 activity either directly through G protein signaling or by transactivation of EGFR via P2Y2R interaction with Src (14, 70). Because EGFR activation has been reported to promote sAPP{alpha} release (71), we investigated whether Src-dependent transactivation of the EGFR was involved in UTP-induced sAPP{alpha} release. However, inhibition of EGFR tyrosine phosphorylation by AG1478 or inhibition of Src by the pyrazole pyrimidine-type 2 inhibitor did not affect UTP-induced sAPP{alpha} release (data not shown), suggesting that Src-mediated EGFR transactivation is not involved. Similar to the P2Y2R, sAPP{alpha} release due to activation of M1 (72) or M3 muscarinic receptors (66, 73) occurs primarily by MAPK- and PKC-independent pathways. These data suggest that P2Y2 and muscarinic receptor-mediated stimulation of sAPP{alpha} release are coupled to an as yet unidentified signaling pathway, which highlights the mechanistic diversity of GPCR-mediated APP processing.

In recent years, several studies have identified and characterized secretases responsible for APP processing (58, 74–77). These secretases belong to the furin-dependent metalloprotease/disintegrin family of proteins referred to as ADAMs, proteolytic enzymes that catalyze ectodomain shedding of proteins to release an active peptide into the extracellular milieu. The TNF-{alpha}-converting enzyme TACE/ADAM17 was originally described as the main protease responsible for TNF-{alpha} release from membranes (48, 78) and was proposed to be the {alpha}-secretase responsible for APP processing (79). Recently, ADAM9 and ADAM10, two metalloprotease family members among the 30 cloned, have also been proposed to be {alpha}-secretases responsible for processing APP (77). Our data demonstrate that inhibition of the expression of ADAM10 or ADAM17/TACE with siRNAs results in a decrease in both UTP-stimulated sAPP{alpha} release and PMA-stimulated sAPP{alpha} release, whereas co-suppression of ADAM10 and ADAM17/TACE completely prevents UTP- or PMA-stimulated sAPP{alpha} release (Fig. 8A), implicating ADAM10 and ADAM17/TACE as the primary {alpha}-secretases involved. Furthermore, the inhibition of sAPP{alpha} release by the furin inhibitor CMK (Fig. 7) supports the conclusion that furin-dependent metalloproteases/disintegrins are responsible for {alpha}-secretase-dependent APP processing in 1321N1-P2Y2 cells.

In conclusion, this study provides the first evidence for the regulation of APP processing by any P2 nucleotide receptor subtype. Our results indicate that P2Y2R-mediated APP processing is regulated by extracellular calcium, but not by increases in [Ca2+]i, and is partially dependent on ERK1/2, but not PKC. Furthermore, we have demonstrated that P2Y2R-mediated sAPP{alpha} release in 1321N1-P2Y2 cells is largely due to the activities of the furin-dependent secretases ADAM10 and ADAM17/TACE. Proteolytic processing of APP by {alpha}-secretase occurs within the sequence of A{beta}, thus precluding the formation of the amyloidogenic and neurodegenerative A{beta} fragment (44–46). Additionally, the {alpha}-secretase product sAPP{alpha} has both neuroprotective and mitogenic effects (29–33). Therefore, activation of P2Y2Rs in the brain may promote neuronal viability.


   FOOTNOTES
 
* This study was supported by National Institutes of Health Grants 1 P01-AG18357 and 1 P20-RR15565 and the University of Missouri-Columbia Food for the 21st Century Program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Biochemistry, 540E Life Sciences Center, 1201 Rollins Rd., University of Missouri-Columbia, Columbia, MO 65211-7310. Tel.: 573-882-5005; Fax: 573-884-2537; E-mail: weismang{at}missouri.edu.

1 The abbreviations used are: P2Y2R, P2Y2 receptor; A{beta}, amyloid-{beta} peptide; ADAM, a disintegrin and metalloprotease; APP, amyloid-{beta} precursor protein; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N,-trimethylammonium salt; CMK, decanoyl-Arg-Val-Lys-Arg-chloromethylketone; EGF, epidermal growth factor; EGFR, EGF receptor; ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; MAPK, mitogen-activated protein kinase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; sAPP{alpha}, ectodomain of APP generated by {alpha}-secretase; siRNA, small interfering RNA; TNF-{alpha}, tumor necrosis factor-{alpha}; TACE, TNF-{alpha} converting enzyme; TAPI-2, TNF-{alpha} protease inhibitor. Back

2 M. Wang and G. A. Weisman, unpublished results. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ralevic, V., and Burnstock, G. (1998) Pharmacol. Rev. 50, 413–492
  2. Schwiebert, E. M., and Zsembery, A. (2003) Biochim. Biophys. Acta 1615, 7–32
  3. Lustig, K. D., Erb, L., Landis, D. M., Hicks-Taylor, C. S., Zhang, X., Sportiello, M. G., and Weisman, G. A. (1992) Biochim. Biophys. Acta 1134, 61–72
  4. Erb, L., Sullivan, D. M., Parr, C. E., Boucher, R. C., Turner, J. T., and Weisman, G. A. (1994) Drug Dev. Res. 31, 267 (abstr.)
  5. Parr, C. E., Sullivan, D. M., Paradiso, A. M., Lazarowski, E. R., Burch, L. H., Olsen, J. C., Erb, L., Weisman, G. A., Boucher, R. C., and Turner, J. T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3275–3279
  6. Turner, J. T., Weisman, G. A., and Camden, J. M. (1997) Am. J. Physiol. 273, C1100–C1107
  7. Ahn, J. S., Camden, J. M., Schrader, A. M., Redman, R. S., and Turner, J. T. (2000) Am. J. Physiol. 279, C286–C294
  8. Schrader, A. M., Camden, J. M., and Weisman, G. A. (2005) Arch. Oral Biol. 50, in press
  9. Seye, C. I., Gadeau, A. P., Daret, D., Dupuch, F., Alzieu, P., Capron, L., and Desgranges, C. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 3602–3610
  10. Seye, C. I., Kong, Q., Erb, L., Garrad, R. C., Krugh, B., Wang, M., Turner, J. T., Sturek, M., Gonzalez, F. A., and Weisman, G. A. (2002) Circulation 106, 2720–2726
  11. Lazarowski, E. R., and Boucher, R. C. (2001) News Physiol. Sci. 16, 1–5
  12. Weisman, G. A., Turner, J. T., and Fedan, J. S. (1996) J. Pharmacol. Exp. Ther. 277, 1–9
  13. Boarder, M. R., Weisman, G. A., Turner, J. T., and Wilkinson, G. F. (1995) Trends Pharmacol. Sci. 16, 133–139
  14. Liu, J., Liao, Z., Camden, J., Griffin, K. D., Garrad, R. C., Santiago-Perez, L. I., Gonzalez, F. A., Seye, C. I., Weisman, G. A., and Erb, L. (2004) J. Biol. Chem. 279, 8212–8218
  15. Seye, C. I., Yu, N., Gonzalez, F. A., Erb, L., and Weisman, G. A. (2004) J. Biol. Chem. 279, 35679–35686
  16. Erb, L., Liu, J., Ockerhausen, J., Kong, Q., Garrad, R. C., Griffin, K., Neal, C., Krugh, B., Santiago-Perez, L. I., Gonzalez, F. A., Gresham, H. D., Turner, J. T., and Weisman, G. A. (2001) J. Cell Biol. 153, 491–501
  17. Weerasinghe, D., McHugh, K. P., Ross, F. P., Brown, E. J., Gisler, R. H., and Imhof, B. A. (1998) J. Cell Biol. 142, 595–607
  18. Kaido, T., Perez, B., Yebra, M., Hill, J., Cirulli, V., Hayek, A., and Montgomery, A. M. (2004) J. Biol. Chem. 279, 17731–17737
  19. Jones, J. I., Prevette, T., Gockerman, A., and Clemmons, D. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2482–2487
  20. Murdoch, C., and Finn, A. (2000) Blood 95, 3032–3043
  21. Seye, C. I., Yu, N., Jain, R., Kong, Q., Minor, T., Newton, J., Erb, L., Gonzalez, F. A., and Weisman, G. A. (2003) J. Biol. Chem. 278, 24960–24965
  22. Mattson, M. P. (1997) Physiol. Rev. 77, 1081–1132
  23. Selkoe, D. J. (2001) Physiol. Rev. 81, 741–766
  24. Selkoe, D. J. (1994) Annu. Rev. Cell Biol. 10, 373–403
  25. Mills, J., and Reiner, P. B. (1999) J. Neurochem. 72, 443–460
  26. Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L., and Beyreuther, K. (1989) Cell 57, 115–126
  27. Oltersdorf, T., Ward, P. J., Henriksson, T., Beattie, E. C., Neve, R., Lieberburg, I., and Fritz, L. C. (1990) J. Biol. Chem. 265, 4492–4497
  28. Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., and Selkoe, D. J. (1992) Nature 357, 500–503
  29. Wallace, W. C., Akar, C. A., and Lyons, W. E. (1997) Brain Res. Mol. Brain Res. 52, 201–212
  30. Bowes, M. P., Masliah, E., Otero, D. A., Zivin, J. A., and Saitoh, T. (1994) Exp. Neurol. 129, 112–119
  31. Smith-Swintosky, V. L., Pettigrew, L. C., Craddock, S. D., Culwell, A. R., Rydel, R. E., and Mattson, M. P. (1994) J. Neurochem. 63, 781–784
  32. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydel, R. E. (1993) Neuron 10, 243–254
  33. Barger, S. W., Van Eldik, L. J., and Mattson, M. P. (1995) Brain Res. 677, 167–170
  34. Nitsch, R. M., Slack, B. E., Farber, S. A., Schulz, J. G., Deng, M., Kim, C., Borghesani, P. R., Korver, W., Wurtman, R. J., and Growdon, J. H. (1994) J. Neural Transm. Suppl. 44, 21–27
  35. Checler, F. (1995) J. Neurochem. 65, 1431–1444
  36. Nitsch, R. M., Wurtman, R. J., and Growdon, J. H. (1995) Arzneim. Forsch. 45, 435–438
  37. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H. (1992) Science 258, 304–307
  38. Lee, R. K., Wurtman, R. J., Cox, A. J., and Nitsch, R. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8083–8087
  39. Nitsch, R. M., Deng, A., Wurtman, R. J., and Growdon, J. H. (1997) J. Neurochem. 69, 704–712
  40. Jolly-Tornetta, C., Gao, Z. Y., Lee, V. M., and Wolf, B. A. (1998) J. Biol. Chem. 273, 14015–14021
  41. Nitsch, R. M., Deng, M., Growdon, J. H., and Wurtman, R. J. (1996) J. Biol. Chem. 271, 4188–4194
  42. Nitsch, R. M., Slack, B. E., Farber, S. A., Borghesani, P. R., Schulz, J. G., Kim, C., Felder, C. C., Growdon, J. H., and Wurtman, R. J. (1993) Ann. N. Y. Acad. Sci. 695, 122–127
  43. Davis-Salinas, J., Saporito-Irwin, S. M., Donovan, F. M., Cunningham, D. D., and Van Nostrand, W. E. (1994) J. Biol. Chem. 269, 22623–22627
  44. Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H., and Selkoe, D. J. (1993) J. Biol. Chem. 268, 22959–22962
  45. Buxbaum, J. D., Koo, E. H., and Greengard, P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9195–9198
  46. Wolf, B. A., Wertkin, A. M., Jolly, Y. C., Yasuda, R. P., Wolfe, B. B., Konrad, R. J., Manning, D., Ravi, S., Williamson, J. R., and Lee, V. M. (1995) J. Biol. Chem. 270, 4916–4922
  47. Rooke, J., Pan, D., Xu, T., and Rubin, G. M. (1996) Science 273, 1227–1231
  48. Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K. A., Gerhart, M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton, R. J., March, C. J., and Cerretti, D. P. (1997) Nature 385, 729–733
  49. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265–275
  50. Kim, S. K., Miller, D., Sapienza V. Chen, C. M., Bai, C., Grundke-Iqbal, I., Currie, J., and Wisniewski, H. (1990) Neurosci. Res. Commun. 2, 121–130
  51. Gendron, F.-P. (2003) Biomed. Res. 14, 47–61
  52. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440–3450
  53. Garrad, R. C., Otero, M. A., Erb, L., Theiss, P. M., Clarke, L. L., González, F. A., Turner, J. T., and Weisman, G. A. (1998) J. Biol. Chem. 273, 29437–29444
  54. Turner, J. T., Redman, R. S., Camden, J. M., Landon, L. A., and Quissell, D. O. (1998) Am. J. Physiol. 275, C367–C374
  55. Schultze-Mosgau, A., Katzur, A. C., Arora, K. K., Stojilkovic, S. S., Diedrich, K., and Ortmann, O. (2000) Mol. Hum. Reprod. 6, 435–442
  56. Luttrell, L. M., Della Rocca, G. J., van Biesen, T., Luttrell, D. K., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 4637–4644
  57. Cao, W., Luttrell, L. M., Medvedev, A. V., Pierce, K. L., Daniel, K. W., Dixon, T. M., Lefkowitz, R. J., and Collins, S. (2000) J. Biol. Chem. 275, 38131–38134
  58. Allinson, T. M., Parkin, E. T., Turner, A. J., and Hooper, N. M. (2003) J. Neurosci. Res. 74, 342–352
  59. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massague, J. (1996) J. Biol. Chem. 271, 11376–11382
  60. Le Gall, S. M., Auger, R., Dreux, C., and Mauduit, P. (2003) J. Biol. Chem. 278, 45255–45268
  61. Parkin, E. T., Trew, A., Christie, G., Faller, A., Mayer, R., Turner, A. J., and Hooper, N. M. (2002) Biochemistry (Mosc.) 41, 4972–4981
  62. Seals, D. F., and Courtneidge, S. A. (2003) Genes Dev. 17, 7–30
  63. Anders, A., Gilbert, S., Garten, W., Postina, R., and Fahrenholz, F. (2001) FASEB J. 15, 1837–1839
  64. Endres, K., Anders, A., Kojro, E., Gilbert, S., Fahrenholz, F., and Postina, R. (2003) Eur. J. Biochem. 270, 2386–2393
  65. Racchi, M., Solano, D. C., Sironi, M., and Govoni, S. (1999) J. Neurochem. 72, 2464–2470
  66. Slack, B. E., Nitsch, R. M., Livneh, E., Kunz, G. M., Jr., Eldar, H., and Wurtman, R. J. (1993) Ann. N. Y. Acad. Sci. 695, 128–131
  67. Caporaso, G. L., Gandy, S. E., Buxbaum, J. D., Ramabhadran, T. V., and Greengard, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3055–3059
  68. Blaug, S., Rymer, J., Jalickee, S., and Miller, S. S. (2003) Am. J. Physiol. 284, C897–C909
  69. Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W., and Lee, V. M. (2000) J. Biol. Chem. 275, 2568–2575
  70. Soltoff, S. P. (1998) J. Biol. Chem. 273, 23110–23117
  71. Slack, B. E., Breu, J., Muchnicki, L., and Wurtman, R. J. (1997) Biochem. J. 327, 245–249
  72. Desdouits-Magnen, J., Desdouits, F., Takeda, S., Syu, L.-J., Saltiel, A. R., Buxbaum, J. D., Czernik, A. J., Nairn, A. C., and Greengard, P. (1998) J. Neurochem. 70, 524–530
  73. Buxbaum, J., Ruefli, A., Parker, C., Cypess, A., and Greengard, P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4489–4493
  74. Koike, H., Tomioka, S., Sorimachi, H., Saido, T. C., Maruyama, K., Okuyama, A., Fujisawa-Sehara, A., Ohno, S., Suzuki, K., and Ishiura, S. (1999) Biochem. J. 343, 371–375
  75. Blacker, M., Noe, M. C., Carty, T. J., Goodyer, C. G., and LeBlanc, A. C. (2002) J. Neurochem. 83, 1349–1357
  76. Hotoda, N., Koike, H., Sasagawa, N., and Ishiura, S. (2002) Biochem. Biophys. Res. Commun. 293, 800–805
  77. Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S., and Ishiura, S. (2003) Biochem. Biophys. Res. Commun. 301, 231–235
  78. Moss, M. L., Jin, S. L., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, H. L., Chen, W. J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J. L., and Becherer, J. D. (1997) Nature 385, 733–736
  79. Buxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., and Black, R. A. (1998) J. Biol. Chem. 273, 27765–27767

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Cell Sci.Home page
I. Grimm, N. Messemer, M. Stanke, C. Gachet, and H. Zimmermann
Coordinate pathways for nucleotide and EGF signaling in cultured adult neural progenitor cells
J. Cell Sci., July 15, 2009; 122(14): 2524 - 2533.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Sanz, P. Chiozzi, D. Ferrari, M. Colaianna, M. Idzko, S. Falzoni, R. Fellin, L. Trabace, and F. Di Virgilio
Activation of Microglia by Amyloid {beta} Requires P2X7 Receptor Expression
J. Immunol., April 1, 2009; 182(7): 4378 - 4385.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
K. Baba, K. Okada, T. Kinoshita, and S. Imaoka
Bisphenol A Disrupts Notch Signaling by Inhibiting Gamma-Secretase Activity and Causes Eye Dysplasia of Xenopus laevis
Toxicol. Sci., April 1, 2009; 108(2): 344 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
S.-K. Cha, T. Wu, and C.-L. Huang
Protein kinase C inhibits caveolae-mediated endocytosis of TRPV5
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1212 - F1221.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
G. Burnstock
Physiology and Pathophysiology of Purinergic Neurotransmission
Physiol Rev, April 1, 2007; 87(2): 659 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al.
International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
H. Ohtsu, P. J. Dempsey, and S. Eguchi
ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors
Am J Physiol Cell Physiol, July 1, 2006; 291(1): C1 - C10.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/19/18696    most recent
M500219200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camden, J. M.
Right arrow Articles by Weisman, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camden, J. M.
Right arrow Articles by Weisman, G. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement